Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Overview
Diabetes Therapy is a comprehensive journal dedicated to advancing knowledge in the field of diabetes and related disorders. It focuses on research, treatment, and education, providing a platform for scientists, clinicians, and educators to share their findings and insights. With a multidisciplinary approach, this journal aims to improve the understanding, management, and prevention of diabetes, ultimately enhancing the quality of life for individuals affected by this chronic condition.
Details
Details
Abbr.
Diabetes Ther
Start
2010
End
Continuing
p-ISSN
1869-6953
e-ISSN
1869-6961
Country
United States
Language
English
Specialty
Cardiology & Vascular Diseases
Metrics
Metrics
h-index / Ranks: 7077
52
SJR / Ranks: 4232
938
CiteScore / Ranks: 3827
6.00
JIF / Ranks: 2461
3.8
Recent Articles
1.
Stougaard E, Curovic V, Hansen T
Diabetes Ther
. 2025 Mar;
PMID: 40088324
Combination therapy is a cornerstone of modern type 2 diabetes management, extending beyond traditional goals of glucose, blood pressure, and lipid control to focus on therapies protecting the heart and...
2.
Hansen T, Ripa R
Diabetes Ther
. 2025 Mar;
PMID: 40048055
Microangiopathy is a key complication of diabetes, adversely effecting several organs including the heart, kidneys, eyes, and nerves. This review focuses on myocardial microvascular dysfunction, a condition characterized by altered...
3.
Peng X, Klingensmith G, Hsia D, Xie Y, Czerniak R, Tamborlane W, et al.
Diabetes Ther
. 2025 Mar;
PMID: 40032809
Introduction: There is an unmet need for pharmacological therapies for children with type 2 diabetes mellitus (T2DM). We assessed the efficacy and safety of an oral dipeptidyl peptidase-4 inhibitor, alogliptin,...
4.
Kome A, Yang A, Gee P, Klein K
Diabetes Ther
. 2025 Mar;
PMID: 40032808
People living with type 2 diabetes mellitus (T2DM) are at risk of developing diabetes-related complications such as chronic kidney disease (CKD). Screening for CKD is considered the standard of diabetes...
5.
de Torres-Sanchez A, Ampudia-Blasco F, Murillo S, Bellido V, Amor A, Mezquita-Raya P
Diabetes Ther
. 2025 Feb;
PMID: 40019699
Introduction: For decades, glycaemic variability (GV) was ignored in clinical practice because its precise assessment was challenging and there were no specific recommendations to reduce it. However, the current widespread...
6.
Li W, Wang Y, Liu C, Yu Y, Xu L, Dong B
Diabetes Ther
. 2025 Feb;
PMID: 40016574
Introduction: The dawn phenomenon (DP), characterized by early morning hyperglycemia, poses a significant challenge in diabetes management and is associated with increased glycemic variability and long-term complications. Despite its clinical...
7.
Rasouli N, Wilding J, Kwan A, Paik J, Sharma P, Peleshok J
Diabetes Ther
. 2025 Feb;
PMID: 40016573
Introduction: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the US for treating type 2 diabetes (T2D) and obesity, has demonstrated significant improvements in glycated hemoglobin A1c...
8.
Fernando K, Alabraba V, Welsh J, Seidu S, Strain W, Bell H, et al.
Diabetes Ther
. 2025 Feb;
PMID: 40016572
Introduction: Type 2 diabetes (T2D) imposes significant personal challenges and societal costs. Continuous glucose monitoring (CGM) is recognised as a state-of-the-art tool, but remains underutilised. Adoption of CGM in primary...
9.
Hassanein M, Alawadi F, AlKadhim I, Aly H, Bajawi D, Cinar T, et al.
Diabetes Ther
. 2025 Feb;
PMID: 40016571
Introduction: Oral semaglutide, a glucagon-like peptide 1 receptor agonist, requires administration on an empty stomach with up to 120 mL of water, followed by no intake of food, beverages, or...
10.
Li Y, Kar S, Li C, Liu M, Luan Z, Yuan G, et al.
Diabetes Ther
. 2025 Feb;
PMID: 40016570
Introduction: This post hoc analysis evaluated subgroup data from China (Chinese mainland, n = 100; Taiwan, n = 45) in ONWARDS 3, a 26-week, randomized, double-blind, double-dummy, treat-to-target, phase 3a...